Imatinib treatment dramatically improved severe pulmonary hypertension, reducing TRPG from 45 to 28 mmHg and BNP from 439 to 51 pg/mL in a patient with PTTM associated with metastatic breast cancer.
Case Report (n=1)
No
Does imatinib improve respiratory dysfunction and pulmonary hypertension in a patient with PTTM associated with metastatic breast cancer?
Imatinib may be effective in improving severe pulmonary hypertension and respiratory dysfunction in patients with PTTM associated with metastatic breast cancer.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare malignancy-related respiratory complication, showing rapid progression of respiratory dysfunction and pulmonary hypertension (PH). Accumulating evidence suggests that imatinib, a platelet-derived growth factor (PDGF) receptor-tyrosine kinase inhibitor, might be effective and improve severe PH in patients with PTTM associated with gastric cancer. However, its efficacy in PTTM with breast cancer is generally believed as very limited. We experienced a rare case of PTTM associated with metastatic breast cancer, a rare case who were treated with imatinib, exhibiting significant improvement of respiratory dysfunction and PH.
Yoshikawa et al. (Tue,) conducted a case report in Pulmonary tumor thrombotic microangiopathy (PTTM) associated with metastatic breast cancer (n=1). Imatinib was evaluated on Improvement in pulmonary hypertension and respiratory dysfunction. Imatinib treatment dramatically improved severe pulmonary hypertension, reducing TRPG from 45 to 28 mmHg and BNP from 439 to 51 pg/mL in a patient with PTTM associated with metastatic breast cancer.